Health and Healthcare

Major Pharma Continues to See Rising Tide in Short Interest

Thinkstock

The short interest data have been released for the September 15 settlement date. Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study come back negative or a candidate not be approved. Conversely, if a drug is approved or passes a clinical trial, there can be big upside.

Drug prices may be under pressure due to the campaign rhetoric and under scrutiny, but if generic drugs are going to keep increasing in market share of existing drugs, then there would seem to be a reason for owning major pharmaceuticals.

The September 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest has increased.

Keep in mind that short sellers betting against big pharma are taking on an added risk. They have to pay out the ongoing high dividends on top of the cost of borrowing the shares.

Pfizer Inc. (NYSE: PFE) saw its short interest increase to 42.43 million shares from the previous 39.45 million. Shares of Pfizer closed Monday at $33.64, within a 52-week trading range of $28.25 to $37.39.

Merck & Co. Inc. (NYSE: MRK) had a small rise in short interest to 30.49 million shares, from 30.01 million in the previous period. Its shares closed Monday at $62.15, in a 52-week range of $47.97 to $64.00.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) short interest increased to 10.81 million shares. The previous level was 9.83 million. Shares closed Monday at $50.27, in a 52-week range of $48.01 to $66.55.

Bristol-Myers Squibb Co. (NYSE: BMY) saw its short interest increase to 13.96 million shares from the previous reading of 12.34 million. Shares closed Monday at $55.48, within a 52-week range of $55.02 to $77.12.

AbbVie Inc. (NYSE: ABBV) short interest fell to 37.79 million shares, compared to the previous 39.05 million. Shares of AbbVie closed Monday at $64.07, in a 52-week trading range of $45.45 to $68.12.

Take Charge of Your Retirement In Just A Few Minutes (Sponsor)

Retirement planning doesn’t have to feel overwhelming. The key is finding expert guidance—and SmartAsset’s simple quiz makes it easier than ever for you to connect with a vetted financial advisor.

Here’s how it works:

  1. Answer a Few Simple Questions. Tell us a bit about your goals and preferences—it only takes a few minutes!
  2. Get Matched with Vetted Advisors Our smart tool matches you with up to three pre-screened, vetted advisors who serve your area and are held to a fiduciary standard to act in your best interests. Click here to begin
  3. Choose Your  Fit Review their profiles, schedule an introductory call (or meet in person), and select the advisor who feel is right for you.

Why wait? Start building the retirement you’ve always dreamed of. Click here to get started today!

 

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.

AI Portfolio

Discover Our Top AI Stocks

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.

You can follow him investing $500,000 of his own money on our top AI stocks for free.